J&J는 EGFRxMET 이중항체 ‘아미반타맙 (제품명 리브리반트)’와 유한양행이 개발해 J&J에 라이선스아웃한 3세대 EGFR TKI ‘레이저티닙 (제품명 라즈클루즈)’가 타크리소 대비 환자의 OS를 통계적으로, 임상적으로 유의미하게 개선했다고 밝힘.
Johnson & Johnson has announced that its chemotherapy-free combination of Rybrevant® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
This combination therapy is the first to show a survival benefit over the current standard of care in the first-line treatment of EGFR-mutated lung cancer. The improvement in median OS is expected to exceed one year.
These findings are based on the Phase 3 MARIPOSA study, which previously demonstrated that the Rybrevant and lazertinib combination significantly reduced the risk of disease progression or death by 30% compared to osimertinib.
In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE™ (marketed as LACLAZA in Korea). LAZCLUZE™ is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR.